The level of BCR-ABL1 kinase activity before treatment does not identify myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib
Date
2009
Authors
Khorashad, J.
Wagner, S.
Greener, L.
Marin, D.
Reid, A.
Milojkovic, D.
Patel, H.
Willimott, S.
Rezvani, K.
Gerrard, G.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Haematologica: the hematology journal, 2009; 94(6):861-864
Statement of Responsibility
Jamshid Sorouri Khorashad, Simon Wagner, Liat Greener, David Marin, Alistair Reid, Dragana Milojkovic, Hetal Patel, Shaun Willimott, Katy Rezvani, Gareth Gerrard, Sandra Loaiza, John Davis, John Goldman, Junia Melo, Jane Apperley, and Letizia Foroni
Conference Name
Abstract
Imatinib is currently the first line therapy for newly diagnosed patients with chronic myeloid leukemia. However, 20–25% of patients do not achieve durable complete cytogenetic responses. The mechanism underlying this primary resistance is unknown, but variations in BCR-ABL1 kinase activity may play a role and can be investigated by measuring the autophosphorylation levels of BCR-ABL1 or of a surrogate target such as Crkl. In this study we used flow cytometry to investigate the in vitro inhibition of Crkl phosphorylation by imatinib in CD34⁺ cells in diagnostic samples from two groups of patients distinguished by their cytogenetic response. No difference in inhibition of Crkl phosphorylation was observed in the two groups. The observation that increasing the dose of imatinib in vivo did not increase the level of cytogenetic response in some non-responders suggests that in at least a proportion of patients imatinib resistance may be due to activation of BCR-ABL1-independent pathway.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright © 2009 by Ferrata Storti Foundation